---
title: "Artelo Biosciences, Inc. (ARTL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ARTL.US.md"
symbol: "ARTL.US"
name: "Artelo Biosciences, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-21T15:56:35.694Z"
locales:
  - [en](https://longbridge.com/en/quote/ARTL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ARTL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ARTL.US.md)
---

# Artelo Biosciences, Inc. (ARTL.US)

## Company Overview

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company’s product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [artelobio.com](https://artelobio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.07 | 67 | - | - | - |
| PB | 0.15 | 7 | 14.61 | 7.97 | 5.09 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-19T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.42 |
| Highest Target | 54.00 |
| Lowest Target | 54.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ARTL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ARTL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ARTL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ARTL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**